ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:01 2024-04-25 pm EDT			5-day change	1st Jan Change
183.4 ^USD	-0.20%		+3.27%	+6.63%

Apr. 25	ResMed Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Rise After Hours	MT
Apr. 17	Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	RE

Tranche Update on ResMed Inc.'s Equity Buyback Plan announced on February 27, 2014.

August 12, 2022 at 06:22 am EDT

From April 1, 2022 to June 30, 2022, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 7,120,221 shares, representing 5.06% for $413.38 million under the buyback announced on February 27, 2014.

Latest news about ResMed, Inc.

ResMed Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Rise After Hours	Apr. 25	MT
Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	Apr. 17	RE
Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	Apr. 01	MT
ResMed Inc. Announces the U.S. Launch of the AirFit F40	Mar. 06	CI
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight	Mar. 05	MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31	Mar. 04	MT
FTSE 100 Edges Higher on Leap Day, Boosted by Howden Joinery, Haleon Gains	Feb. 29	DJ
Australia shares slip as biotech firm CSL slumps on failed drug trial (Feb 12)	Feb. 11	RE
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating	Jan. 30	MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating	Jan. 30	MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating	Jan. 25	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Jan. 25	MT
Oppenheimer Raises ResMed Price Target to $185 From $175, Maintains Outperform Rating	Jan. 25	MT
RBC Lifts Price Target on ResMed to $182 From $181, Cites 'Solid' Fiscal Q2 Results, Keeps Sector Perform Rating	Jan. 25	MT
ResMed Fiscal Q2 Non-GAAP Earnings, Revenue Increase; Shares Rise Premarket	Jan. 25	MT
ResMed Posts Lower Fiscal Q2 Profit; Shares Up 7%	Jan. 24	MT
ResMed Declares Q4 Dividend; Shares Jump 7%	Jan. 24	MT
ResMed beats estimates on strong sleep apnea device sales	Jan. 24	RE
ResMed Resumes Share Buyback Program With $50 Million of Repurchases in Fiscal Q2	Jan. 24	MT
ResMed Keeps Quarterly Cash Dividend at $0.48 a Share, Payable March 14 to Holders of Record Feb. 8	Jan. 24	MT
ResMed Fiscal Q2 Non-GAAP Earnings, Revenue Increases; Shares Jump After-Hours	Jan. 24	MT
ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024	Jan. 24	CI
Transcript : ResMed Inc., Q2 2024 Earnings Call, Jan 24, 2024	Jan. 24

Chart ResMed, Inc.

Duration

Period

More charts

Company Profile

ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows: - medical devices (50.4%); - masks (37.9%); - software as a service (11.7%). At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia. The United States accounts for 61.4% of net sales.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ResMed, Inc. continues to make headway in the sleep market

December 11, 2023 at 05:55 am EST

More Strategies

Ratings for ResMed, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

183.4 USD

Average target price

206.1 USD

Spread / Average Target

+12.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
RESMED, INC.	+6.63%	26.99B
THERMO FISHER SCIENTIFIC	+7.71%	220B
DANAHER CORPORATION	+6.25%	185B
INTUITIVE SURGICAL, INC.	+10.60%	133B
BOSTON SCIENTIFIC CORPORATION	+26.73%	107B
SIEMENS HEALTHINEERS AG	-0.57%	62.91B
EDWARDS LIFESCIENCES CORPORATION	+15.42%	53.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.89%	47.71B
AGILENT TECHNOLOGIES, INC.	-1.91%	40.29B
GE HEALTHCARE TECHNOLOGIES INC.	+11.16%	39.57B

Other Advanced Medical Equipment & Technology